ArticleCancer cell2015
Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers.
0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 218 citations in OpenAlex.
- Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.European urology oncology · 2018Trial
- Development of a GPCR-binding ligand screening method using real-time interaction analysis on live cells.Biochemistry and biophysics reports · 2026Article
- Malaria and cancer: common features and interactions.Trends in parasitology · 2026Review
- Chondroitin sulfate shapes the unfolded protein response in osteosarcoma to sustain cancer cell survival during ER stress.Cell death & disease · 2026Article
- Bugs as drugs: parasite biomolecules as novel therapeutics against breast cancer.American journal of physiology. Cell physiology · 2026Review
- Glancing at the role of Toxoplasma gondii in neuro-oncology: from risk factor to therapeutic target.Infectious agents and cancer · 2026Review
- Oncofetal chondroitin sulfate positive circulating tumor cells as prognostic biomarkers in early-stage melanoma.Scientific reports · 2026Article
- Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate.Cell death & disease · 2026Article
- TGF-β-induced epithelial to mesenchymal transition drives proteoglycan binding specificity of HPV-based drug conjugates for cancer cells.Frontiers in oncology · 2026Article
- Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in PDAC.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Protein catenation potentiates antitumor activity of malaria VAR2CSA navigation CAR-T cells in a mouse model of hematological malignancies.Journal for immunotherapy of cancer · 2025Article
- Glycan Profiling Identifies Chondroitin-4-sulfate as a Biomarker for Platinum Response and Therapeutic Target in Ovarian Cancer.bioRxiv : the preprint server for biology · 2025Article
- Bridging the gap for diverse applications of parasites as advanced cancer therapeutics: current progress and future directions.Infectious agents and cancer · 2025Review
- Malaria: past, present, and future.Signal transduction and targeted therapy · 2025Review
- Targeting Oncofoetal Chondroitin Sulphate Allows Identification of Tumour-Derived Extracellular Vesicles.Journal of extracellular vesicles · 2025Article
- Revealing a novel Decorin-expressing tumor stromal subset in hepatocellular carcinoma via integrative analysis single-cell RNA sequencing.Cancer cell international · 2025Article
- Multi-cancer detection of circulating tumor cells by targeting oncofetal chondroitin sulfate.NPJ precision oncology · 2025Article
- Unveiling the anti-neoplastic potential of Schistosoma mansoni-derived antigen against breast cancer: a pre-clinical study.European journal of medical research · 2025Article
- The Potential of Nanotechnology in Anti-cancer Drug to Regulate Nrf2 Signaling for Cancer Therapeutic Purposes.Current medicinal chemistry · 2025Review
- An Overview of the Dichotomous Role of Microbiota in Cancer Progression and Management.Current cancer drug targets · 2025Review
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 7 institutions in 4 countries.
Ali SalantiDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark. Electronic address: salanti@sund.ku.dk.
Thomas M ClausenDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada.
Mette Ø AgerbækDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Nader Al NakouziVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Madeleine DahlbäckDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Htoo Zarni OoVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Sherry LeeVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
Tobias GustavssonDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Jamie R RichKairos Therapeutics, Inc., Vancouver, BC V6T 1Z3, Canada; Centre for Drug Research and Development, Vancouver, BC V6T 1Z3, Canada.
Bradley J HedbergKairos Therapeutics, Inc., Vancouver, BC V6T 1Z3, Canada; Centre for Drug Research and Development, Vancouver, BC V6T 1Z3, Canada.
Yang MaoDepartment of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
Line BaringtonDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Marina A PereiraDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Janine LoBelloTranslational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.
Makoto EndoGenetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC V6H 3Z6, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada; Department of Anatomic Pathology, Kyushu University, Fukuoka 812-8582, Japan; Department of Orthopaedic Surgery, Kyushu University, Fukuoka 819-0395, Japan.
Ladan FazliVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
Jo SodenRetrogenix Ltd., Crown House, Bingswood Estate, Whaley Bridge, High Peak SK23 7LY, UK.
Chris K WangVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
Adam F SanderDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Robert DagilDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Susan ThraneDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Peter J HolstDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Le MengDepartment of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
Francesco FaveroCentre for Biological Sequence Analysis, Technical University of Denmark, Lyngby 2800, Denmark.
Glen J WeissTranslational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA; Cancer Treatment Centers of America, Goodyear, AZ 85338, USA.
Morten A NielsenDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Jim FreethRetrogenix Ltd., Crown House, Bingswood Estate, Whaley Bridge, High Peak SK23 7LY, UK.
Torsten O NielsenGenetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC V6H 3Z6, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada.
Joseph ZaiaDepartment of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
Nhan L TranTranslational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.
Jeff TrentTranslational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.
John S BabcookKairos Therapeutics, Inc., Vancouver, BC V6T 1Z3, Canada; Centre for Drug Research and Development, Vancouver, BC V6T 1Z3, Canada.
Thor G TheanderDepartment of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
Poul H SorensenDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada.
Mads DaugaardVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada. Electronic address: mads.daugaard@ubc.ca.
University of Copenhagen · DKTranslational Genomics Research Institute · USUniversity of British Columbia · CABoston University · USCentre for Drug Research and Development · CAKyushu University · JPTechnical University of Denmark · DK
Funding
Mass Spectrometry Resource for Biology and MedicineP41GM104603 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COSTELLO, CATHERINE E. · 2012 to 2017
$10.4MQuantitative profiling of glycosaminoglycans from breast tumor tissue arraysR21CA177479 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZAIA, JOSEPH · 2014 to 2016
$712kNCI NIH HHS R21 CA177479NIGMS NIH HHS P41 GM104603
Abstract
Plasmodium falciparum engineer infected erythrocytes to present the malarial protein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS) exclusively expressed in the placenta. Here, we show that the same CS modification is present on a high proportion of malignant cells and that it can be specifically targeted by recombinant VAR2CSA (rVAR2). In tumors, placental-like CS chains are linked to a limited repertoire of cancer-associated proteoglycans including CD44 and CSPG4. The rVAR2 protein localizes to tumors in vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds strongly inhibits in vivo tumor cell growth and metastasis. Our data demonstrate how an evolutionarily refined parasite-derived protein can be exploited to target a common, but complex, malignancy-associated glycosaminoglycan modification.
Indexed as
AnimalsAntigens, ProtozoanCell Line, TumorChondroitin Sulfate Proteoglycan 4Chondroitin Sulfate ProteoglycansChondroitin SulfatesFemaleHEK293 CellsHumansHuman Umbilical Vein Endothelial CellsHyaluronan ReceptorsMelanoma, ExperimentalMembrane ProteinsMiceMolecular Targeted TherapyOligopeptidesAntigens, ProtozoanCD44 protein, humanChondroitin Sulfate Proteoglycan 4Chondroitin Sulfate ProteoglycansChondroitin SulfatesCSPG4 protein, humanhemiasterlinHyaluronan ReceptorsMembrane ProteinsOligopeptidesRecombinant ProteinsVAR2CSA protein, Plasmodium falciparum
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.